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A kinetic study of cation transport from uremic patients. We previ-
ously described in red blood cells (RBCs) from uremic patients on
dialysis a reduction in sodium (Na) effiux through the Na, potassium (K)
cotransport system (Na,K CoT) while Na efflux through the Na,K
pump was normal. We then examined Na effiux in fresh cells and in
cells loaded to obtain one level of intracellular sodium (Na1) concentra-
tion at about 25 mmol/liter cell. In the present study we used similar
cation flux methodology to examine the kinetics of cation efflux through
the Na,K pump and Na,K CoT in uremic patients on dialysis. RBCs
were Na-loaded to attain five different levels of Na1 concentration over
a range of 5 to 50 mmollliter cells using the ionophore nystatin. At each
level of Na-loading, the Na1 achieved was similar in RBCs from controls
and patients. Ouabain—sensitive Na efflux through the Na,K pump
showed no difference in rate between normals and dialysis patients.
When the kinetic parameters of this transport pathway were consid-
ered, the apparent affinity (K05) for sodium was not significantly
different between controls and patients (18.4 2,3 vs. 20.0 2.6
mmol/liter cell) and the maximal velocity of efflux (Vmax) was also not
different between controls and patients (9.6 0.7 vs. 8.5 1.2
mmol/liter celllhr). Comparison of Naractivated Na versus K effiux
rates through the Na,K CoT in normal subjects demonstrated similar
saturation kinetics, (I( 15.8 3.3 vs. 12.2 2.8 mmol/liter cell, Vmx
0,81 0.1 vs. 0.78 0.1 mmol/liter celllhr) consistent with the known
stoichiometric ratio of I Na: I K:2 Cl described for this mechanism. In
dialysis patients Na-activated, Na,K CoT-mediated Na effiux was
markedly reduced. Analysis of the kinetic parameters of Na1-activated
Na efflux showed that the reduced RBC Na,K CoT is due to reduction
ifl Vmax and not to a change in K05. Maximum furosemide—sensitive K
effiux rate was also reduced in dialysis patients. However, instead of
exhibiting the anticipated saturation kinetics observed for Na, the K
effiux rates were high at low levels of Na1 and remained unchanged with
increasing Na1 concentrations. Ouabain— and furosemide—resistant Na
and K effiuxes were not significantly different between normals and
dialysis patients. We conclude that Na effiux through RBC Na,K pump
is intact over a wide range of Na1 concentrations in dialysis patients. On
the other hand, the furosemide—sensitive co-effiux of Na and K, which
in normal RBCs displayed a typical 1 Na to 1 K transport characteristic,
was quantitatively and qualitatively altered in dialysis patients. The
maximum effiux rate of both Na and K was reduced and in addition, the
usual stoichiometric ratio for Na and K exit through this furose-
mide—sensitive pathway was no longer observed.
Cation content and sodium (Na) transport in uremic RBCs
have been studied to delineate the effect of chronic renal failure
on ionic cellular transport mechanisms [1—31. Most recent
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studies have focused on the ouabain—sensitive Na, potassium
(K) pump in RBCs from chronically hemodialyzed patients
[4—6]. However, in the human RBC, Na transport is mediated
through other pathways, including the ouabain—insensitive,
furosemide—sensitive Na,K cotransport system (Na,K CoT)
and the Na,Li counter transport system (Na,Li CTT). We have
previously found in RBCs from patients undergoing chronic
intermittent hemodialysis and chronic ambulatory peritoneal
dialysis (CAPD), normal intracellular Na (Na1) and K content,
normal Na and K passive permeability, and normal Na efflux
through the Na,Li CTT and the Na,K pump. We did observe,
however, a markedly reduced Na efflux through the Na,K CoT
[71. This observation has also been noted by others [8, 9]. In
order to further characterize the ouabain—sensitive and —insen-
sitive cation transport pathways in patients undergoing dialysis,
we examined the kinetics of Na efflux through the Na,K pump
and Na and K effluxes through the Na,K CoT in RBCs, by
measuring cation effluxes at five Na1 concentrations
Methods
Subjects
Fourteen Caucasian males with end—stage renal disease
(ESRD) and receiving chronic intermittent hemodialysis were
studied. Clinical and biochemical findings are depicted in Table
1. The age range was 29 to 68 years (mean 58.0 3.6). The
etiologies of ESRD and the number of patients, in parenthesis,
were as follows: chronic glomerulonephritis (4) polycystic
kidney disease (4), diabetic nephropathy (2), essential hyper-
tension (2) chronic interstitial nephritis (1), and Alport's syn-
drome (1). The control population consisted of six females and
eight males; eleven subjects were Caucasian and three subjects
were Oriental. The age of the controls ranged from 23 to 48
years (mean 40.8 6.7) and all were normotensive with no
significant medical problems.
Methods
RCBs preparation. Fresh venous blood was drawn between
0800 and 1000 hours in control subjects and in patients just
before starting hemodialysis. Blood was collected into heparin.
ized tubes, centrifuged at 3,000 g and the plasma and buffy coat
were removed by aspiration. RBCs were washed four times
with a washing solution containing 152 m choline chloride, 1
mM MgCI2, 10 ms Tris-Mops, pH 7.4 at 4°C.
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Nystatin—loading procedure. The procedure is that of
Canessa et at [10] which is modified from Cass and Dalmark [11]
using lower amounts of the ionophore to facilitate complete
removal by washings. The nystatin—loading solution contained
55 mM sucrose and 140 m total cations containing a mixture of
NaCI and KCI. The Na and K concentrations in the loading
solution were reciprocally changed according to the final Na1
desired. Na-loading was carried out at five different levels of
external Na1 from 8 to 70 m (Fig. 1). One ml of packed cells
from the cell suspension was added to S ml of cold loading
Age yr 58.0 3.6
Weight kg 78.6 3.6
Systolic blood pressure mm Hg 150.0 5.6
Diastolic blood pressure mm Hg 80.0 3.2
Hemoglobin gIdl 10.2 0.8
MCV mm3 84.6 2.6
MCHC % 34.3 1.6
Blood urea nitrogen mgldl 72.8 3.4
Serum creatinine mgldl 13.6 0.7
Albumin gIdi 3.0 0.1
Serum Na mEqiliter 137.0 1.0
Serum K mEqiliter 4.9 1.5
Serum HCO3 mEqiliter 18.2 1.0
Serum Ca mgldl 9.5 0.2
Serum P mg/dl 4.9 0.3
solution containing 40 tg/ml of nystation dissolved in DMSO,
and the cell suspension incubated for 20 minutes at 4°C. After
centrifugation and removal of the supernatant, the cells were
incubated for another 20 minutes in 5 ml of the same loading
solution but without nystatin. Then nystatin removal was done
by washing the cells four times at room temperature again using
the same loading solution but now with the addition of 1 mivi of
K phosphate buffer, 10 m glucose and 0.1% albumin at pH 7.4.
In order to remove the external cations, five additional washes
were done using the choline chloride wash solution (described
above) at 4°C. Changes in cell volume during nystatin—loading
was determined by measuring the hemoglobin per liter cell in
fresh and loaded cells.
Intracellular cations. Aliquots of a 50% cell suspension were
taken for hematocrit and intracellular Na and K determination
in fresh and Na-loaded RBCs. Washed RBCs were completely
lysed in 0.02% Acationex detergent (American Scientific Prod-
ucts, McGraw Park, Illinois, USA). After centrifugation, the
Na and K concentrations in the supernatant were measured
using an atomic absorption spectrophotometer (Model 5000,
Perkin Elmer, Norwalk, Connecticut, USA). Results are ex-
pressed in mmollliter cell.
Cation efflux measurements. The ouabain—sensitive fraction
of Na efflux was measured in Na-loaded RBCs, suspended at
1% Hct in an efflux medium containing 130 m choline chloride
and 10 mrvi KC1 with and without 0.1 mrvi ouabain. The efflux
times were 5 and 25 minutes at 37°C, with triplicate samples.
The furosemide—sensitive Na and K effluxes were measured in
a 2% Hct suspension of RBCs in an medium containing 140 mM
choline and 0.1 mM ouabain with or without 1.0 mtvi furosemide.
The incubation times were 5 and 65 minutes, and all measure-
ments were done in triplicate samples. All the media used for
measuring cation effluxes through Na,K CoT also contained 1
m of MgCI2, 10 ms'i glucose and 10 mrvi Tris-Mops, pH 7.4 at
37°C and were Na and K free. The length of incubation was
selected in order to measure cation fluxes during their linear
rates. The Na,K pump activity was estimated as the difference
in Na accumulation in the efflux media with and without
ouabain. The difference in Na and K accumulation between the
efflux media with and without furosemide was estimated as
Na,K CoT activity.
Data analysis. Cation efflux rates are expressed in mmol/liter
Table L Clinical and biochemical parameters in
dialysis patients (N = 14)
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Fig. 1. Intracellular sodium (Na1) and potassium (K1) concentrations
simultaneously achieved at each level of Na-loading in 14 normal
controls (0) and 14 dialysis patients (z).
8.0
6.0
Co
E 4.0
o 2.0
0
Fig. 2. Ouabain—sensitive Na efflux rates as a function offive levels of
intracellular Na concentrations in normal controls (0) and dialysis
patients (s).
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Table 2. Kinetic parameters for cation effluxes through the Na,K pump and Na,K CoT
Na,K pump
Naefflux
Na,K CoT
Naefflux KeflThx
a
0.5
0
max
V a0.5 t bmax 1/ a0.5 maxb
-
Controls (N = 14)
Patients (N = 14)
18.4 2.3
20.0 2.6
9.6 0.7
8.5 1.2
15.8
14.9
3.0
2.8
0.81
0.30
0.1
0.!
12.2 2.8
—
0.78
—
0.1
a mmol/liter cell
b mmol/liter cell/hr
Fig. 3. Furosemide—sensitive Na efflux rates as a function offive levels
of intracellular Na+ concentrations in normal controls (0) and dialysis
patients (s).
Fig. 4. Furosem ide—sensitive K efflux rates as a function offive levels
of intracellular Na concentrations in normal controls (0) and dialysis
patients (s).
cell/hr. Data are reported as mean SEM. Statistical signifi-
cance was determined using Student's unpaired t-test. Kinetic
parameters (K05 and Vmax) of Na-activated Na efflux through
the Na,K pump were calculated according to the Hanes—Woolf
Plot [12]. The same equation was used to calculate the kinetic
parameters of Na and K effluxes through the Na,K CoT.
Results
Intracellular cation and cell volume.
In fresh RBCs there was no significant difference between
controls and patients in mean intracellular Na (7.2 0.4 vs. 7.1
0.5 mmol/liter cell) or K (96.2 3.6 vs. 95.9 3.3 mmol/litet
cell). With nystatin Na-loading there was no difference in the
level of Na1 achieved between controls and patients (Fig. 1).
Determination of hemoglobin concentration in fresh cells and at
the five final Na, showed mild cell shrinkage with recovery of 98
3% of the initial volume in both study groups.
Na,K pump.
Figure 2 depicts mean values for ouabain—sensitive Na efflux
rates as a function of increasing concentrations of Na,. There
was no significant difference in ouabain—sensitive Na efflux rate
at all five levels of Na between controls and dialysis patients.
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Calculation of the K05 and Vrnax using the Hanes—Woolf plot for
Na,K pump mediated Na efflux showed no difference between
normals and dialysis patients in either of the two parameters
(Table 2).
Na,K Cotransport
Na,K CoT, estimated as furosemide—sensitive Na efilux were
markedly reduced in dialysis patients at each level of Na1 as
depicted in Figure 3. The calculated K05 for Na efflux through
the Na,K CoT was not different between the two study groups,
while the Vmax was markedly reduced in dialysis patients (Table
2). We also examined the furosemide—sensitive K efflux as a
function of increasing Na1 (Fig. 4). In normal subjects, K effiux
increased with increasing Na in a fashion similar to the Na
efflux with a calculated K05 of 12.2 2.8 mmol/liter cell and
Vmax of 0.78 0.1 mmol/liter cell/hr. In contrast, Na,K
CoT-mediated K fflux in dialysis patients was independent of
the changes in Na1
Ouabain— and furosemide—insensitive fluxes
Ouabain and furosemide—resistant Na efflux increased pro-
gressively with increasing Na and were similar at every level of
Na-loading for both study groups (Fig. 5). Ouabain— and
furosemide—resistant K efflux was slightly higher in dialysis
patients but the difference was not significant.
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An important consideration in interpreting Na,K CoT func-
tion in dialysis patients is the change in intracellular volume in
RBCs during Na-loading. Furosemide—sensitive Na,K CoT in
nucleated RBCs is sensitive to acute volume changes [14, 15],
the pathway being suppressed by cell swelling and stimulated
by cell shrinkage. In human RBCs cation fluxes can also be
altered by cell volume changes [16—18] but the effect on Na,K
CoT is variable. Adragna et al [17, 18] demonstrated that
decreasing RBC water content by both osmotic and non-
osmotic methods did not change Na,K CoT activity whereas
increasing RBC intracellular water greater than 6% decreased
furosemide—sensitive Na efflux, and increased furosemide—
resistant K efflux. The methodology of the nystatin Na-loading
procedure is designed to maintain cell volume relatively con-
—1 stant. Nonetheless, there was a 2 to 3% reduction in cell
60 volume, as reflected by hemoglobin concentration, during the
loading procedure in normal RBCs and in those from dialysis
patients. Based on the findings of the above studies [16, 18],
alterations in RBC volume in our study would still not be
expected to influence Na,K CoT activity. Thus, in dialysis
patients the marked decrease in furosemide—sensitive Na efflux
cannot be accounted for by cell volume alterations. Duhm and
Gobel [19] also described in human RBCs a positive correlation
between furosemide—sensitive Na,K CoT and mean cellular
hemoglobin—concentration (MCHC). As MCHC was not de-
creased in dialysis patients, this factor could not account for the
change in Na,K CoT in this population.
A second alteration in the RBC Na,K CoT pathway in
dialysis patients is the complete uncoupling of 1:1 relationship
between Na1-activated Na and K effluxes. Thus, there was an
40 absence of correlation between Na1 concentrations and K efflux
rates in RBCs from patients compared to the typical saturation
kinetics in controls. This dissociation of the coupling of cations
through the Na,K CoT in dialysis patients has no readily
apparent explanation but could represent an alternative furose-
mide—sensitive K pathway, such as the Ca k-dependent K
efflux pathway first described by Gardos [20]. This pathway,
however, seems to require the presence of external K in the
millimolar range in order to be activated [21], whereas in this
study Na,K CoT assays were performed in media free of
external K. An alternative explanation is that the recently
described K,Cl CoT [22] could predominate in uremia. Both
pathways, however, display only weak inhibition by furosemide
[22].
Many of the original studies of ouabain—sensitive Na,K pump
in renal failure patients reported reduced values in frankly
uremic subjects [1—3]. With the advent of dialysis and sampling
of a less severely ill population both normal [4, 6] and abnormal
[5] Na,K pump function has been found. We previously re-
ported [7, 8] normal RBC ouabain—sensitive Na efflux in RBCs
from dialysis patients studied both in cells Na-loaded to one
level of Na1 and in fresh cells. The results of the present study
confirm the presence of almost identical pump—mediated Na
efflux rates in dialysis patients and controls over a wide range of
RBC Na1. Analysis of kinetic parameters shows similar K05 and
Vmax in cells from both study groups. Hence, as measured by
RBC Na-efilux methodology, the Na,K pump can perform at
maximal capacity in optimally dialyzed patients.
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Fig. 5. Ouabain— and furosemide—resistant Na and K efflux rates as a
function of five levels of (A) intracellular sodium (Na1) and (B) potas-
sium (K,) concentrations in normal controls (0) and dialysis patients
(s).
Discussion
The present study extends our previous results to examine
Na,K CoT-mediated outward Na and K fluxes in RBCs from
dialysis patients. We used nystatin to Na-load RBCs to five
different levels of Na1 in a range from below physiologic levels
to levels fivefold greater. The results indicate that in RBCs from
dialysis patients there is a normal K05 but a major reduction in
Vmax for Na efflux through the Na,K CoT. As previously noted,
this markedly reduced Na,K CoT is found in almost all uremic
patients and occurs independently of blood pressure level or
level of RBC Na,K CoT activity observed in first degree
relatives [7]. Na and K effluxes through the Na,K CoT have
been found to be reduced in RBCs from some patients with
essential hypertension [13]. Analysis of the kinetic parameters
of Na,K CoT in essential hypertension show an abnormality in
the K05 with only a minority of subjects displaying a reduction
in the Vmax [13]. These findings contrast with Na,K CoT-
mediated Na efflux in dialysis patients where K005 is normal but
there is a marked reduction in Vmax occurring independent of
the presence or absence of hypertension.
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